Claims for Patent: 7,968,569

Summary for Patent: 7,968,569

Title:	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
Abstract:	Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s):	Zeldis; Jerome B. (Princeton, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	10/438,213
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,968,569
Patent Claims:	1. A method of treating multiple myeloma, which comprises cyclically administering to a patient having multiple myeloma about 5 to about 25 mg per day of a compound of the formula: ##STR00009## or a pharmaceutically acceptable salt thereof, for 21 consecutive days followed by seven in combination with 40 mg per day dexamethasone. 2. The method of claim 1, wherein the multiple myeloma is smoldering myeloma, indolent myeloma, chemotherapy responsive multiple myeloma, refractory myeloma, relapsed myeloma, or relapsed and refractory Dune-Salmon stage III multiple myeloma. 3. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt. 4. The method of claim 1, wherein the multiple myeloma is relapsed, refractory or resistant to previous therapy. 5. The method of claim 1, wherein the compound and dexamethasone are administered orally. 6. The method of claim 5, wherein the compound is administered in the form of a capsule or tablet. 7. The method of claim 1, wherein the compound is administered in an amount of from about 10 to about 25 mg per day. 8. The method of claim 1, wherein the compound is administered in an amount of about 5, 10, 20, or 25 mg per day. 9. The method of claim 7, wherein the compound is administered in an amount of about 25 mg per day. 10. The method of claim 1, wherein the compound is administered in an amount of 5 mg per day. 11. The method of claim 7, wherein the compound is administered in an amount of 10 mg per day. 12. The method of claim 1, wherein the compound is administered in a capsule of 5 mg, 10 mg, 15 mg or 25 mg. 13. A method of treating multiple myeloma, which comprises administering, on a 28 day cycle, to a patient having multiple myeloma: (a) about 25 mg per day of a compound of the formula: ##STR00010## or a pharmaceutically acceptable salt thereof, for 21 consecutive days followed by seven consecutive days of rest from administration of said compound, and; (b) 40 mg per day of dexamethasone on days 1-4 every 28 days. 14. The method of claim 12, wherein the capsule comprises the compound, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate. 15. The method of claim 1, wherein said dexamethasone is administered.